P3 Health Partners Inc
Q2 2025 Earnings
Market Reaction
S&P 500 over the same 30 days: +2.45%.
Did PIII Beat Earnings? Q2 2025 Results
P3 Health Partners delivered a disappointing second quarter, posting revenue of $355.79 million, a 6.2% decline year-over-year that fell short of the $359.43 million consensus estimate by roughly 1%, while a diluted loss per share of $6.23 stood in stark contrast to the breakeven expectation on Wall Street. The primary culprit was a wave of prior-period adjustments tied to payer settlements, which compressed medical margin to $30.61 million; stripping out those items, medical margin would have reached $39.30 million, a figure management says better reflects the company's operational trajectory. Interest expense nearly doubled to $10.14 million from $5.44 million a year ago, amplifying pressure on a balance sheet already navigating going concern risks. In response, P3 cut its full-year 2025 guidance, now projecting revenues of $1.35 billion to $1.50 billion and an Adjusted EBITDA loss of $69 million to $39 million, citing a single underperforming payer relationship. Still, management pointed to flat medical cost trends and $120 million to $170 million in identified EBITDA improvement opportunities as reasons for confidence in reaching sustained profitability by 2026.
- Flat medical cost trends despite industry-wide inflation
- 10% improvement in per-member funding year-over-year when adjusted for prior-period items
- Network and payer rationalization driving 9% decline in at-risk membership
- Three of four markets already EBITDA positive or breakeven
“Our core business continues to strengthen as we execute on our $130 million EBITDA improvement plan. While we faced prior period headwinds, we've successfully managed medical cost trends to remain flat while improving funding across our membership on a per-member basis. With an additional $120 to $170 million in identified EBITDA opportunities and three of our four markets already EBITDA positive or breakeven, P3 is well-positioned to achieve sustained profitability in 2026 and beyond.”
P3 Health Partners CEO, on the earnings call
Forward Guidance & Outlook
P3 revised its full-year 2025 guidance downward to reflect prior-period adjustment impacts and underperformance of a single payer. The company now expects at-risk members of 109,000-119,000, total revenues of $1,350-$1,500 million, medical margin of $124-$154 million ($90-$111 PMPM), and Adjusted EBITDA loss of ($69)-($39) million. Management identified $120-$170 million in additional EBITDA improvement opportunities for 2026 and stated P3 is well-positioned to achieve sustained profitability in 2026 and beyond, with three of four markets already EBITDA positive or breakeven.
PIII YoY Financials
PIII Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.